Product Images Aprepitant

This is a description for Aprepitant Capsules, USP containing 40mg of aprepitant. The capsules are for adult use only, and the package is a bulk package not for dispensing and is not child-resistant. The product is manufactured by Pharmathen International S.A. and marketed by GSMS, Incorporated. The usual adult dosage information is available in the accompanying prescribing information. The capsules should be stored at 20 to 25°C with excursions permitted to 15° to 30°C. Barcode placement is indicated on the packaging.*

This text provides information about Aprepitant Capsules, USP containing 80 mg aprepitant, USP per capsule for adults and pediatric patients 12 years of age and older. It indicates that the product is not child-resistant and is meant for bulk packaging only. The manufacturer is Pharmathen International S.A. and it is marketed by GSMS, Incorporated. It mentions the usual dose instructions and storage conditions. The text also includes the manufacturer's address in Greece and the marketing company's address in the USA. The product is only for prescription (Rx only) and includes a barcode placement section.*

This text is a description of Aprepitant Capsules, USP in a dosage strength of 125mg. It is intended for use in adults and pediatric patients aged 12 years and older. The capsules are not child-resistant and come in a bulk package for distribution. The manufacturing details include the company Pharmathen International S.A in Greece and distribution by GSMS, Incorporated in the USA. Storage instructions recommend keeping the capsules at 20 to 25°C, with excursions permitted to 15° to 30°C. The usual dose and further prescribing information are provided separately.*

This text provides information about Aprepitant Capsules, USP, in 80 mg and 125 mg strengths for adults and pediatric patients 12 years and older. It includes dosage instructions for a 3-day pack to be taken around chemotherapy treatment. The text also contains storage instructions, manufacturer details, and guidelines for taking the capsules.*

This text provides results from two studies comparing the effectiveness of Aprepitant Regimen versus Standard Therapy. The data includes the number of participants in each group and outcome measures taken at various time points up to 120 hours. A log rank test was used to determine statistical significance, with a p-value less than 0.001 reported for both studies. Please note that the results are nominal and not adjusted for multiplicity.*

This text appears to show data from two different studies evaluating the effectiveness of two different regimens (Aprepitant and Standard Therapy) in chemotherapy cycles. The number of participants in each group for both studies is provided, along with the results for each chemotherapy cycle. This data may be useful for comparing the effectiveness of Aprepitant and Standard Therapy in managing chemotherapy side effects.*